Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

HER2 Positive Gastric Cancer Market Snapshot (2023 to 2033)

The global HER2-positive gastric cancer market is currently valued at US$ 1261.8 Million in 2023 and is anticipated to expand at a CAGR of 3.5%. Owing to the technological advances in healthcare the market is likely to propel to US$1779.8 Million by 2033.

“The increase in disease burden and approval of pipeline candidates are likely to drive the growth of the HER2 positive market in the forecast period.”

Report Attribute Details
Expected Market Value (2023) US$ 1261.8 Million
Projected Forecast Value (2033) US$ 1779.8 Million
Global Growth Rate (2023 to 2033) 3.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

HER2 Positive Gastric Cancer Market Revenue Analysis 2017 to 2022 vs. Future Outlook 2023 to 2033

The HER2-positive gastric cancer market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 3.5% in the above-mentioned forecast period.

The stomach cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers.

Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the HER2-positive gastric cancer market.

What Market Trends Are Influencing the HER2 Positive Gastric Cancer Market?

The Approval of New Targeted and Immunotherapy Drugs Is Expected to Fuel the Market Growth During the Forecast Period

The increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the globe. Major drivers for the stomach cancer market are treatment advancements, combination therapies, an increasing number of cancer treatment centers

Quick approvals from the regulatory authorities regarding HER2-positive gastric cancer drugs may bring immense growth prospects for the gastric cancer drugs market. Research and development activities play an important role in developing novel drugs and therapies.

For instance, in January 2021, the US FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.

Increasing Healthcare Awareness to Boost the Market Growth

Health awareness amongst the population is rising which results in the prediction of drugs boosting the market growth. The innovative launches in medications for treating HER 2-positive gastric cancer are expected to prompt the market simultaneously.

Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market. An increase in the incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma; a rise in alcohol consumption, a surge in smoking, and an increase in the geriatric population are anticipated to boost the growth of the global HER 2 positive gastric cancer testing market during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors Are Restraining the Growth of the HER2 Positive Gastric Cancer Market?

Stringent Government Regulation for Drug Approval May Restrain The Market Growth

Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges that are likely to pose a threat to its growth during the forecast period.

The lack of understanding of intratumoral heterogeneity, erosion in innovator sales, like the launch of biosimilars, and lack of universal guidelines for the assessment of HER2 overexpression or amplification may restrain the growth of the market during the forecast period.

The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.

Country-Wise Insights

What Makes the US an Attractive Market for HER2 Positive Gastric Cancer?

Increasing cancer cases in the region drive the market growth in North America

North America dominated the market and accounted for the largest revenue share of around 3.4% in 2023. The rising prevalence of gastric cancer is driving the growth of the HER2-positive gastric cancer market in North America.

Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease.1,2 Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.

Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.

The rising adoption of targeted cancer therapy and the availability of advanced technology in cancer research and treatment centers boost the market growth in the region.

For instance, in May 2020 AstraZeneca and Daiichi Sankyo Company, Limited has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Why is the HER2 Positive Gastric Cancer Market in Europe Expected to Be Highly Opportunistic?

Increase in Significant Research and Development Investments in Healthcare to Boost the Market Growth

Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population.

Furthermore, the rising company activities in conducting clinical trials for developing effective drugs for patients suffering from HER2-positive gastric cancer as well as increasing product launches and approvals in the region are expected to fuel the market growth.

For instance, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Which Factors Are Supporting Growth of the HER2 Positive Gastric Cancer Market in Asia Pacific?

Advancement in Healthcare to Propel the Market Growth

Asia Pacific is anticipated to expand at the fastest CAGR of % during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing Research and Development in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease are anticipated to propel regional growth.

Furthermore, advancements in healthcare infrastructure, rising government spending on healthcare policies, and the presence of important members in Asia Pacific all contribute to the growth of the global HER2-positive gastric cancer market.

Country-wise Forecast CAGRs for the HER2 Positive Gastric Cancer Market

The UK 3.3%
India 3.1%
South Korea 3.3%
China 3.2 %
The USA 3.4 %

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

Based on Therapy Type, Which Is the Most Prominent Segment in The HER 2 Positive Gastric Cancer Market?

Targeted Therapy Segment remains dominant among other types

Based on the therapy, the targeted therapy accounted for the largest market share in 2023. This is attributed to the increased adoption of targeted therapy along with the chemotherapy and rise in awareness regarding combination therapies for gastric cancer. HER-2 inhibitor trastuzumab is the only molecular targeted drug approved by the US Food and Drug Administration (FDA) for the first-line treatment of HER-2-positive advanced gastric cancer. The segment held a revenue share of over 55.4% in 2023

Therefore, the rising prevalence of gastric cancer and increased usage of targeted therapy in combination with different other therapies has fostered the growth of this segment in the past few years.

Immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among patients regarding the effectiveness and benefits of immunotherapy over chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like the FDA and EMA in the approval of immunotherapy drugs is expected to augment the demand for immunotherapy drugs for the treatment of Her2-positive gastric cancer.

By End-User, Which Segment Generates High Revenue in HER2 Positive Gastric Cancer Market?

Hospital and Speciality Clinics Dominated the Market

The Hospital and speciality clinics segment dominated the Her 2 positive gastric cancer therapy market in 2023 with a revenue share of over 35.0%. Initiatives by regional governments to develop healthcare infrastructure is expected to drive the segment growth during the forecast period. Based on the end-user, the market has been segmented into hospitals and speciality and ambulatory surgery centres.

The ambulatory surgery centre segment accounted for the second-largest share in 2021. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.

Start-up Scenario

How do New Entrants Contribute to the HER2 Positive Gastric Cancer Market?

With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the HER2-positive Gastric Cancer market.

Some of the start-ups in the HER2-positive Gastric Cancer market include-

  • Novocodex Biopharmaceuticals - Nvocode is a developer of antibodies for the treatment of cancer. The company is designing biopharmaceutical anti-HER2 (product code: NCB001), a monoclonal antibody-conjugated drug through non-natural amino acid insertion technology for the coupling of toxins on mAb. It is used for the treatment of HER2, positive recurrent breast cancer, and gastric cancer.
  • VCell provides a biosimilar product for curing autoimmune diseases. The products provided are Remsima mainly used to treat autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis, Truxima anti-tumor biosimilar product mainly used to treat non-Hodgkin's lymphoma and other hematological tumors and rheumatoid arthritis. Herzuma is mainly used for the treatment of HER2-positive breast and gastric cancer.
  • Abscint, developer of radiolabelled single domain antibodies to diagnose cancer and cardiac diseases, offers ABSCINT-HER2 for the detection of HER2 positive cells in the brains and ABSCINT-206 for the detection of immune cells in granuloma CD-206 positive macrophages in the heart.
  • ASLAN Pharmaceuticals is an oncology-focused company developing a portfolio of targeted drugs, focusing on gastric, bile duct, and breast cancers. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are ASLAN001 which is a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer, and gastric cancer, and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET receptor tyrosine kinases, being developed in gastric and breast cancer.

Competitive Landscape

Key pharmaceutical companies that are working efficiently in the HER2-positive Gastric Cancer space include names like AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG, and others.

The manufacturers are involved in the production of HER2-positive Gastric Cancer in a larger capacity. Research and innovation are also conducted to launch innovative products for HER2-positive Gastric Cancer.

Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.

  • In May 2021, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • On September 20, 2022 - CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs.
  • In December 2022 - Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 1 clinical trial (NCT05394168) of the company’s HLX53, an anti-TIGIT Fc fusion protein, for the treatment of advanced or metastatic solid tumors or lymphomas in China.

Report Scope

Report Attribute Details
Growth Rate CAGR from 2023 to 2033
Expected Market Value (2023) US$1261.8 Million
ProjectedForecast Value (2033) US$1779.8 Million
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million & CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis
Segments Covered
  • Therapy
  • Stage
  • End-user
  • Regions
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia-Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • The USA
  • Canada
  • Brazil
  • Mexico
  • Benelux
  • France
  • Germany
  • Italy
  • Nordic
  • Spain
  • The UK
  • Poland
  • Russia
  • India
  • Malesia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
  • Hutchison Medipharma
  • LintonPharm
  • Shanghai Henlius Biotech
  • Sanofi
  • Pfizer
  • Novartis AG
Customization Available Upon Request

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

HER2 Positive Gastric Cancer Market by End-User:

  • Ambulatory surgery centers,
  • Hospitals and Specialty clinics
  • Others

HER2 Positive Gastric Cancer Market by Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia-Pacific
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the expected valuation of HER2 positive gastric cancer market?

The global Her 2 positive gastric cancer market is likely to reach a valuation of US$ 1261.8 Million by the end of 2023.

Who are the key players in HER2 positive gastric cancer market?

AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm are some of the key players in the global HER2 positive gastric cancer market

What are the future prospects for HER2 positive gastric cancer market sales?

Sales of HER2 positive gastric cancer market are likely to expand at 3.5% CAGR through 2033.

Which are the top 5 countries driving demand for biopharma plastics?

The US, Canada, Japan, China, & Germany are expected to drive most of the demand for HER2 positive gastric cancer market.

What will be the global HER2 positive gastric cancer market revenue total by 2033?

By the end of 2033, the global market for HER2-positive gastric cancer market is predicted to reach a valuation of US$1779.8 Million

Table of Content

1. Executive Summary | HER2 Positive Gastric Cancer Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        5.3.1. Chemotherapy

        5.3.2. Immunotherapy

        5.3.3. Radiation Therapy

        5.3.4. Targeted Therapy

        5.3.5. Surgery

    5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Stage, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage, 2023 to 2033

        6.3.1. Stage I

        6.3.2. Stage II

        6.3.3. Stage III

        6.3.4. Stage IV

    6.4. Y-o-Y Growth Trend Analysis By Stage, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Stage, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Ambulatory Surgery Centers

        7.3.2. Hospitals and Specialty Clinics

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. Asia-Pacific

        8.3.6. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The US

            9.2.1.2. Canada

        9.2.2. By Therapy

        9.2.3. By Stage

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy

        9.3.3. By Stage

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapy

        10.2.3. By Stage

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy

        10.3.3. By Stage

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Benelux

            11.2.1.2. France

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. Nordic

            11.2.1.6. Spain

            11.2.1.7. The UK

            11.2.1.8. Rest of Western Europe

        11.2.2. By Therapy

        11.2.3. By Stage

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy

        11.3.3. By Stage

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Rest of Eastern Europe

        12.2.2. By Therapy

        12.2.3. By Stage

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy

        12.3.3. By Stage

        12.3.4. By End User

    12.4. Key Takeaways

13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Australia

            13.2.1.6. New Zealand

            13.2.1.7. Rest of APAC

        13.2.2. By Therapy

        13.2.3. By Stage

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy

        13.3.3. By Stage

        13.3.4. By End User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Therapy

        14.2.3. By Stage

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy

        14.3.3. By Stage

        14.3.4. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. The US

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Therapy

            15.1.2.2. By Stage

            15.1.2.3. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Therapy

            15.2.2.2. By Stage

            15.2.2.3. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Therapy

            15.3.2.2. By Stage

            15.3.2.3. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Therapy

            15.4.2.2. By Stage

            15.4.2.3. By End User

    15.5. Benelux

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Therapy

            15.5.2.2. By Stage

            15.5.2.3. By End User

    15.6. France

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Therapy

            15.6.2.2. By Stage

            15.6.2.3. By End User

    15.7. Germany

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Therapy

            15.7.2.2. By Stage

            15.7.2.3. By End User

    15.8. Italy

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Therapy

            15.8.2.2. By Stage

            15.8.2.3. By End User

    15.9. Nordic

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Therapy

            15.9.2.2. By Stage

            15.9.2.3. By End User

    15.10. Spain

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Therapy

            15.10.2.2. By Stage

            15.10.2.3. By End User

    15.11. The UK

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Therapy

            15.11.2.2. By Stage

            15.11.2.3. By End User

    15.12. Poland

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Therapy

            15.12.2.2. By Stage

            15.12.2.3. By End User

    15.13. Russia

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Therapy

            15.13.2.2. By Stage

            15.13.2.3. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Therapy

            15.14.2.2. By Stage

            15.14.2.3. By End User

    15.15. Malaysia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Therapy

            15.15.2.2. By Stage

            15.15.2.3. By End User

    15.16. Singapore

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Therapy

            15.16.2.2. By Stage

            15.16.2.3. By End User

    15.17. Thailand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Therapy

            15.17.2.2. By Stage

            15.17.2.3. By End User

    15.18. Australia

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Therapy

            15.18.2.2. By Stage

            15.18.2.3. By End User

    15.19. New Zealand

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Therapy

            15.19.2.2. By Stage

            15.19.2.3. By End User

    15.20. GCC Countries

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Therapy

            15.20.2.2. By Stage

            15.20.2.3. By End User

    15.21. South Africa

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Therapy

            15.21.2.2. By Stage

            15.21.2.3. By End User

    15.22. Israel

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Therapy

            15.22.2.2. By Stage

            15.22.2.3. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Therapy

        16.3.3. By Stage

        16.3.4. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. AstraZeneca

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Bayer

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Bristol-Myers Squibb

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Ono Pharmaceutical Co. Ltd

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Hutchison Medipharma

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. LintonPharm

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Shanghai Henlius Biotech

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Sanofi

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Pfizer 

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Novartis AG

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Gastric Electrical Stimulators Market

Published : August 2023

Healthcare

Gastric Space-Occupying Devices Market

Published : July 2022

Healthcare

Gastric Bands Market

Published : October 2021

Explore Healthcare Insights

View Reports

HER2 Positive Gastric Cancer Market